Solventum Corporation

Solventum to Report Third Quarter Fiscal 2026 Earnings on November 5, 2026

Solventum will release its third quarter fiscal 2026 financial results on Thursday, November 5, 2026, after the U.S. market close. Management will host a webcast at 3:30 p.m. CST / 4:30 p.m. EST the same day, with a replay and supplemental materials available on the investor relations site.

•10d ago

Wound Care Stocks Are Posting Double-Digit Growth. Here’s Why.

This GlobeNewswire item is a paid promotional commentary by Wall Street Investor whose featured subject is Conexeu Sciences (CNXU), not the filer Axogen. Axogen appears only as sector context: Q2 2026 revenue of $69.7 million, up 23.1%, with Breast segment growth above 50% and FY2026 guidance raised to at least $279 million. The disclaimer confirms the publisher was compensated to promote Conexeu and that Axogen and other named companies are 'not peers, competitors, or financial comparables' and not involved in the article.

•19d ago

Solventum to Participate in the 2026 Wells Fargo Healthcare Conference

Solventum management will participate in a fireside chat at the Wells Fargo Healthcare Conference on Wednesday, Sept. 9, 2026, beginning at approximately 10:15 a.m. EDT in Boston, MA. A live webcast and archived replay of the fireside chat will be available on the company's investor relations site at investors.solventum.com. This is a routine conference-appearance notice with no financial results, guidance, or business news attached; no share-price impact is expected absent new commentary from the event itself.

•1mo ago

The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For

A sponsored news commentary article highlights a 'tissue gap' in the aesthetics market created by GLP-1 weight-loss drugs, focusing on preclinical company Conexeu Sciences. AbbVie is mentioned as the owner of Allergan Aesthetics and the incumbent leader in injectables, with the article suggesting current fillers like Botox and Juvederm were not engineered for large-volume restoration. No specific financial results or strategic updates were provided for AbbVie.

•2mo ago

SOLV: 8-K · leadership change

Solventum Corporation appointed Neil Zieselman as Senior Vice President, Controller and Chief Accounting Officer, effective August 10, 2026. He succeeds Mary Wilcox, who is retiring, and will report to Chief Financial Officer Wayde McMillan. Mr. Zieselman joins the company from Surgery Partners, Inc., where he served as Senior Vice President, Corporate Finance and Controller. His previous experience includes leadership roles at Stryker Corporation and Covanta Holding Corporation, and he began his career as an auditor at PricewaterhouseCoopers LLP. His compensation package includes a $130,000 cash sign-on bonus and a $600,000 initial grant of restricted stock units vesting over three years. He is also eligible for an annual long-term incentive target award of $500,000 and a target annual bonus of 50% of his base salary.

SEC 8-K•3mo ago

Solventum to Report Second Quarter Fiscal 2026 Earnings on August 5, 2026

Solventum announced it will release its second quarter fiscal 2026 financial results after the market closes on August 5, 2026. Management will host a webcast at 4:30 p.m. EDT to discuss the results and other material information. Replays and supplemental materials will be available on the company's investor relations website.

•3mo ago

SOLV: 8-K · litigation

Solventum Corp (SOLV) filed an 8-K to disclose the resolution of a class action lawsuit filed by Eric Gilbert challenging the company's bylaw amendments. The underlying claims were dismissed as moot after Solventum amended its bylaws, leaving only a dispute over attorney's fees. The company agreed to pay $120,000 in fees and expenses to the plaintiff's counsel to avoid further litigation costs. Solventum explicitly denied all allegations of wrongdoing in the original complaint. The Delaware Court of Chancery entered an order closing the case on June 2, 2026, requiring this 8-K filing as notice to stockholders. This is a routine corporate governance matter with no material financial impact on the company.

SEC 8-K•4mo ago

SOLV: 8-K · leadership change

Solventum Corp filed an 8-K on May 27, 2026, reporting the adoption of a new Executive Severance Plan effective June 1, 2026. The new plan replaces the prior plan effective April 1, 2024, and modifies severance terms for eligible employees, including executive officers. Under the new plan, direct reports of the CEO will generally receive 12 months of base salary upon involuntary termination, down from 18 months under the prior plan for new hires. Currently serving executive officers eligible for 18 months of severance will retain that eligibility for two years. The plan also provides for lump-sum COBRA premium payments and specific vesting treatments for equity awards.

SEC 8-K•4mo ago

Solventum to Participate in the 2026 Jefferies Healthcare Conference

Solventum management will participate in a fireside chat at the Jefferies Healthcare Conference on June 3, 2026. The session is scheduled for approximately 9:55 a.m. EDT in New York. A live stream and archived replay will be available on the company's investor relations website.

•4mo ago

SOLV: 8-K · proxy statement

Solventum Corporation reported the voting results from its annual shareholder meeting held on May 15, 2026. Shareholders elected all four Class II director nominees—Carlos Albán, Susan D. DeVore, Shirley Edwards, and Dr. Bernard A. Harris Jr.—to the Board of Directors for two-year terms. The advisory vote on executive compensation (say-on-pay) was approved with approximately 74% of votes cast in favor, while the ratification of PricewaterhouseCoopers LLP as the independent auditor received overwhelming support with over 96% of votes in favor.

SEC 8-K•5mo ago